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Abstract. Temporomandibular joint dysfunction (TMJD) is 
characterised by clinical symptoms involving both the masti‑
catory muscles and the temporomandibular joint (TMJ). Disc 
internal derangement and osteoarthritis (OA) are the most 
common forms of TMJD. Currently, the molecular process 
associated with degenerative changes in the TMJ is unclear. 
Our previous study showed that elastin‑digested peptides 
act on human TMJ synovial cells and lead to upregulation 
of interleukin‑6 (IL‑6) and metalloelastase‑12 (MMP‑12; an 
elastin‑degrading enzyme) in vitro. However, there is limited 
information regarding the involvement of elastin‑degradation 
by MMP‑12 in the processes of inflammatory responses and 
cartilage degradation in vivo. STR/Ort mice were used as a 
model of TMJ OA in the present study. Significant articular 
cartilage degeneration was observed starting at 20 weeks 
of age in the STR/Ort mice and this progressed gradually 
until 40 weeks, compared with the age‑matched CBA mice. 
Immunostaining analysis showed that MMP‑12 and IL‑6 were 
expressed in the chondrocytes in the superficial zones of the 
cartilage. Immunostaining also showed that aggrecanases 
[a disintegrin and metalloproteinase with thrombospondin 
motifs (ADAMTS)‑4 and ADAMTS‑5] were expressed in 
the chondrocytes in the superficial zones of the cartilage. 
These findings suggest that an inflammatory and degradative 
process was initiated in the TMJ. Harmful mechanical stimuli, 
particularly pressure, may cause damage to the elastin fibres in 
the most elastin‑rich superficial layer of the articular cartilage. 
Elastin‑digested peptides are then generated as endogenous 
warning signals and they initiate a pro‑inflammatory cascade. 
This leads to upregulation of pro‑inflammatory mediators, 
such as IL‑6 and MMP‑12, which further trigger tissue damage 
resulting in elevated levels of elastin‑digested peptides. IL‑6 
increases expression of the aggrecanases ADAMTS‑4 and 
ADAMTS‑5, following cartilage degradation. This leads to 
the establishment of a positive feedback loop and may result 
in chronic inflammation and cartilage degradation of the TMJ 
in vivo.
Introduction
The characteristics of temporomandibular joint dysfunction 
(TMJD) include musculoskeletal conditions and craniofacial 
pain in the masticatory system that involve the joint, masticatory 
muscles or muscle innervations. Various factors are associated 
with the aetiology of TMJD, including growth and develop‑
mental anomalies (1), trauma (2), detrimental body posture (3), 
parafunctional habits and bruxism (4), and stress (5). The most 
common forms of TMJD are disc internal derangement, which 
involves an abnormal anatomical relationship between the 
articular disc and articulating surfaces, and osteoarthritis (OA), 
which involves an abnormal anatomical relationship between the 
articular disc and articulating surfaces (6). Although the degen‑
erative changes in the temporomandibular joint (TMJ) have been 
reported to be related to osteoclastogenesis (7), the molecular 
process underlying these changes are yet to be elucidated.
Previous studies (8‑11) have reported increased concen‑
trations of monocyte–macrophage‑derived cytokines in the 
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synovial fluid of patients with TMJD. The release of protein‑
ases and stimulation of the expression of degrading enzymes 
and inflammatory mediators may be facilitated by various 
cytokines, including interleukin 1β (IL‑1β), interleukin‑6 
(IL‑6) and tumour necrosis factor‑α (TNF‑α), thereby leading 
to inflammation of the TMJ and degradation of bone and carti‑
lage (12). These results highlight the potential role of cytokines 
in TMJD pathogenesis. Our previous study showed that IL‑6 
expression in the synovial fluid obtained from patients with 
TMJD was significantly correlated with the two clinical 
parameters of TMJ locking and pain/jaw function based on 
a visual analogue scale (VAS) (13). Additionally, the concen‑
tration of elastin‑digested peptides in the synovial fluid of 
patients with TMJD was significantly associated with the TMJ 
locking duration, the VAS and IL‑6 expression (13). In vitro, 
elastin‑digested peptides act on human TMJ synovial cells to 
promote IL‑6 upregulation and MMP‑12 (an elastin‑degrading 
enzyme) (13). These findings suggest an inflammation model 
in the TMJ where elastin is degraded by a harmful mechanical 
stimulus, and the degradation products induce a pro‑inflam‑
matory cascade and increase the expression of MMP‑12.
Currently, there is limited information regarding the 
involvement of elastin‑degradation by MMP‑12 in the 
process of inflammatory responses and cartilage degradation 
by aggrecanases [a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS)‑4 and ADAMTS‑5] 
in vivo. The STR/Ort mice often develop spontaneous OA of 
the medial tibial cartilage of the knee joint Thus this mouse 
model is useful in studying the pathogenesis of knee OA (14). 
The histopathological lesions of knee OA in STR/Ort mice 
are progressive and exhibit a high degree of similarity to that 
of human knee OA. Moreover, 85% of STR/Ort mice demon‑
strate histological OA lesions in the medial tibial cartilage by 
the time they are 35 weeks old. Previous reports have shown 
that the STR/Ort mice develop spontaneous OA‑like lesions 
in the TMJ with age, and thus, they may facilitate the study 
of the pathogenesis of TMJ OA (15). The aim of the present 
study was to investigate the role of MMP‑12 and aggrecanases 
in STR/Ort mice with TMJ OA.
Materials and methods
Assessment of the progression and severity of OA. A total of 
24 male STR/Ort mice (age, 10 weeks) and 8 sex‑matched 
CBA control mice were used in the present study. The average 
weight of the STR/Ort mice at the beginning of the experiment 
(age, 10 weeks) was 24.1±1.6 g, whereas that of the CBA control 
mice (age, 10 weeks) was 25.3±1.4 g. The mice TMJs were 
removed by microsurgery and were fixed in 4% paraformalde‑
hyde solution for 24 h at room temperature. Decalcification of 
TMJs was performed using 10% EDTA for 3 weeks at room 
temperature, and subsequently stored in 70% ethanol at 4˚C 
until required for further analysis. Samples were embedded 
in paraffin wax and sectioned sagittally (5‑µm thickness) 
through the entire joint. Safranin‑O (Sigma‑Aldrich; Merck 
KGaA) staining was used at room temperature to evaluate 
proteoglycan loss using a validated scoring system as per 
the Osteoarthritis Research Society International (OARSI) 
recommendations (16). The joints were graded at 10‑µm inter‑
vals through the joint in a blinded manner by two experienced 
investigators, and were scored as follows: 0, normal cartilage; 
0.5, loss of Safranin‑O without structural changes; 1, small 
fibrillations without loss of cartilage; 2, vertical clefts down 
to the layer immediately below the superficial layer and some 
loss of surface lamina; 3, vertical clefts/erosion to the calcified 
cartilage extending to <25% of the articular surface; 4, vertical 
clefts/erosion to the calcified cartilage extending to 25‑50% of 
the articular surface; 5, vertical clefts/erosion to the calcified 
cartilage extending to 50‑75% of the articular surface; and 
6, vertical clefts/erosion to the calcified cartilage extending 
to >75% of the articular surface. Scores were added from all 
levels through the entire joint to obtain the ‘summed score’, 
which reflected the severity of the osteoarthritic lesion. OA 
predominantly affects the mandibular condyle (15); therefore, 
the average of the summed scores at both the sites was used for 
each sample to obtain robust results.
All the animal experiments performed in the present study 
were approved by the Ethics Committee of the Kanazawa 
University Graduate School of Medical Science (approval 
no. 352‑2). The mice were housed in groups of four in indi‑
vidually vented cages maintained at 21˚C±2˚C and a humidity 
range of 30‑70% in a 12‑h light/dark cycle with ad libitum 
access to food and water. The animals were monitored daily 
for any health and/or welfare issues from the time of birth, 
including any possible defects or significant changes in size 
during the first 2 weeks of life. The mice were then sacrificed 
in a chamber by increasing the CO2 concentration at a flow 
rate of 60%/min of volume. Lack of respiration and faded eye 
colour were used to confirm death.
Immunohistochemical analysis. The paraffin embedded 
sagittal sections of TMJs were dewaxed and antigen retrieval 
were performed using Immunosaver (FUJIFILM Wako Pure 
Chemical Corporation) for 45 min at 98˚C. The sections 
were washed in PBS, and then rinsed in PBS containing 
1% BSA and 2% foetal calf serum. Immunohistochemical 
staining was performed with antibodies against MMP‑12 
(cat. no. 22989‑1‑AP; ProteinTech Group, Inc.), IL‑6 (cat. 
no. ab6672; Abcam), ADAMTS‑4 (cat. no. ab185722; Abcam) 
and ADAMTS‑5 (cat. no. ab41037; Abcam). Primary anti‑
bodies were diluted in PBS at a ratio of 1:1,000, and the 
sections were then incubated with primary antibodies over‑
night at 4˚C. Binding of these antibodies was detected using 
EnVision Single Reagents (Dako; Agilent Technologies, Inc.). 
After washing, the slides were incubated with 3,3'‑diamino‑
benzidine tetrahydrochloride (Sigma‑Aldrich; Merck KGaA) 
and immediately rewashed under tap water following colour 
development. Slides were then counterstained with haema‑
toxylin for 3 min at room temperature (FUJIFILM Wako 
Pure Chemical Corporation), mounted with DPX (FUJIFILM 
Wako Pure Chemical Corporation) and observed under a 
light microscope at a magnification of x4‑x100 (Olympus 
Corporation). The specificity of staining was confirmed using 
a Universal Negative Control for IS‑Series Rabbit Primary 
Antibodies (cat. no. IS60061; Dako; Agilent Technologies, 
Inc.) as a negative control, according to the manufacturer's 
protocol. Immunohistochemical staining was graded in a 
blinded manner by two experienced investigators as follows: 
0, no staining, 1; minor staining, 2; marked staining; and 3, 
maximal staining, as described previously (17).
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Statistical analysis. The summed OARSI scores of joints are 
presented using a box‑whisker plot (median ± interquartile 
range). The immunohistochemical scores are presented as the 
mean ± standard error of the mean. There were eight samples in 
both the STR/Ort and CBA groups. For comparisons between 
the samples, data were analysed using Kruskal‑Wallis one‑way 
analysis of variance on ranks with a post‑hoc Dunnett's test 
for summed OARSI scores, or a Mann‑Whitney U test for 
immunohistochemical scores using SPSS version 23 (IBM 
Corp.), as described previously (17,18). P<0.05 was considered 
to indicate a statistically significant difference.
Results
Cartilage degradation of the TMJs in the STR/Ort mice. In 
order to examine the pathogenesis of spontaneous OA, the TMJs 
of STR/Ort mice and control CBA mice were collected and 
sectioned after 10, 20 or 40 weeks. Relative to the age‑matched 
control CBA mice, significant proteoglycan loss was observed 
in the upper zone of the cartilage after 20 weeks of age, and 
this loss was increased after 40 weeks (Fig. 1A). STR/Ort mice 
after 40 weeks exhibited vertical fissures in the matrix into the 
mid zone, and the fissures were branched (Fig. 1A). The data 
of the summed scores showed that significant articular carti‑
lage degeneration started at 20 weeks of age in the STR/Ort 
mice and progressed gradually until they were 40 weeks old; 
this was not observed in the age‑matched CBA mice (Fig. 1B).
Expression of MMP‑12, IL‑6 and aggrecanases. Immuno‑
staining showed that MMP‑12 was expressed in the 
chondrocytes in the superficial zones after 20 weeks in the 
STR/Ort mice, and this increased gradually until the mice 
were 40 weeks old (Fig. 2A). In contrast, MMP‑12 expression 
was detected in the chondrocytes in the CBA mice at all time 
points (Fig. 2A). In the subchondral bone, MMP‑12 expres‑
sion was observed in the osteoblast‑like and osteoclast‑like 
cells, starting at 20 weeks of age in the STR/Ort mice, and 
its levels increased with disease severity until the mice were 
40 weeks old (Fig. 2A). However, no MMP‑12 expression was 
detected in the subchondral bone of the CBA mice, regardless 
of age (Fig. 2A).
IL‑6 was expressed throughout the cartilage of both the 
STR/Ort and CBA mice from 20 weeks of age, with expres‑
sion in the chondrocytes in the superficial zones. However, the 
expression was significantly higher in the STR/Ort cartilage 
after 20 and 40 weeks relative to the age‑matched CBA 
Figure 1. Cartilage degradation of the TMJ in the STR/Ort mice. (A) Safranin‑O staining of sections of the TMJ of the STR/Ort mice and control CBA mice 
after 10, 20 and 40 weeks. Scale bar, 100 µm. (B) Box‑whisker plots representing the summed OARSI scores of TMJs of the STR/Ort mice and control CBA 
mice after 10, 20 and 40 weeks. Results are expressed as the sum of the OARSI scores from each histological section through the joints. Values are expressed 
as the median ± interquartile range. n=8 mice per group. Data were compared using Kruskal‑Wallis one‑way analysis of variance on ranks with a post‑hoc 
Dunnett's test. *P<0.05 vs. CBA control mice. TMJ, temporomandibular joint; OARSI, Osteoarthritis Research Society International; Cont, control.
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mice (Fig. 2B). In the subchondral bone, IL‑6 expression was 
observed in the osteoblast‑like and the osteoclast‑like cells, 
starting at 20 weeks of age in the STR/Ort mice, and its levels 
increased with disease severity until the mice were 40 weeks 
old (Fig. 2B). IL‑6 expression in the subchondral bone in the 
STR/Ort cartilage was significantly higher compared with the 
age‑matched CBA mice, excluding after 10 weeks (Fig. 2B). 
However, no detectable IL‑1β or TNF‑α expression was 
observed in the STR/Ort mice and CBA‑strain mice, irrespec‑
tive of age (data not shown).
ADAMTS‑4 and ADAMTS‑5 were expressed throughout 
the cartilage of both the STR/Ort and CBA mice from 
20 weeks of age, with expression in the chondrocytes in the 
superficial zones that gradually increased till the mice were 
40 weeks old (Fig. 3A and B). ADAMTS‑5 was expressed 
in the middle zone of the cartilage after 40 weeks of age in 
Figure 2. Expression of MMP‑12 and IL‑6 in the TMJ of STR/Ort mice. (A) MMP‑12 or (B) IL‑6 immunostaining of sections and the corresponding histo‑
logical scores of the TMJs from STR/Ort mice and control CBA mice after 10, 20 and 40 weeks. The immunohistochemical scores in cartilage or subchondral 
bone are presented as the mean ± the standard error of the mean. Scale bar, 100 µm. *P<0.05 vs. CBA control mice. Mann‑Whitney U test. MMP‑12, metal‑
loelastase‑12; IL‑6, interleukin‑6; TMJ, temporomandibular joint.
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the STR/Ort mice. ADAMTS‑4 and ADAMTS‑5 expres‑
sion was significantly higher in the STR/Ort cartilage 
compared with the age‑matched CBA mice, excluding 
after 10 weeks (Fig. 3A and B). In the subchondral bone, 
ADAMTS‑4 and ADAMTS‑5 expression was observed in the 
osteoblast‑like and osteoclast‑like cells, starting at 10 weeks of 
age in the STR/Ort mice, and its levels increased with disease 
severity until the mice were 40 weeks old (Fig. 3A and B). 
ADAMTS‑4 and ADAMTS‑5 expression levels were signifi‑
cantly higher in the STR/Ort subchondral bone compared with 
the age‑matched CBA mice (Fig. 3A and B).
Discussion
The primary aim of the present study was to determine 
whether elastin‑degradation by MMP‑12 was involved in 
Figure 3. Expression of the aggrecan‑degrading enzymes, ADAMTS‑4 and ADAMTS‑5, in the TMJ of STR/Ort mice. (A) ADAMTS‑4 or (B) ADAMTS‑5 
immunostaining of sections and the corresponding histological scores of the TMJs of the STR/Ort mice and control CBA mice after 10, 20 and 40 weeks. 
The immunohistochemical scores in the cartilage or subchondral bone are presented as the mean ± standard error of the mean. Scale bar, 100 µm. Data were 
compared using a Mann‑Whitney U test. *P<0.05 vs. CBA control mice. ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; TMJ, 
temporomandibular joint; Cont, control.
YAMASHITA‑FUTANI et al:  ROLE OF MMP‑12 IN TMJ DEGENERATIVE CHANGES6
TMJ inflammatory responses and cartilage degradation by 
aggrecanases in vivo. STR/Ort mice were used as a model 
of TMJ OA. The initial joint pathology caused by OA is 
difficult to characterise in humans as OA is often diagnosed 
in the first instance at an advanced stage. Animal models of 
OA may improve our understanding of the early pathology 
of OA, including loss of proteoglycans and fibrillations. 
Dreessen and Halata (19) showed age‑related osteoarthritic 
degeneration of the TMJ in male STR/1N mice, suggesting a 
systemic basis of the disease. In the present study, significant 
articular cartilage degeneration began at 20 weeks of age in the 
STR/Ort mice and progressed gradually until 40 weeks relative 
to that in the age‑matched CBA mice. The progression that 
was observed until 40 weeks of age in the STR/Ort mice was 
consistent with the results of a previous study (15). Conversely, 
in this same previous study, significant articular cartilage 
degeneration was not observed at 20 weeks of age in STR/Ort 
mice compared with the age‑matched CBA mice (15). The 
maximal OARSI scores in STR/Ort mice at 20 and 40 weeks 
of age were 2 (highest OARSI score was 6). These results 
suggested that TMJ osteoarthritis at 20 and 40 weeks of age in 
STR/Ort mice showed initial or early joint pathology caused 
by OA. Thus, the STR/Ort mouse model may be appropriate 
for facilitating an understanding of the initial pathology of 
TMJ OA.
Elastin fibres are major extracellular matrix macromo‑
lecules that are critical for the maintenance of elasticity and 
resilience of tissues, such as blood vessels, lungs and skin. 
A previous study showed that the architecture of the elastin 
network varies significantly with cartilage depth (20). Dense 
elastin fibres formed a distinctive cobweb‑like meshwork 
parallel to the cartilage surface in the most superficial layer 
of the articular cartilage (20). Contrastingly, in the superficial 
zone, the elastin fibres were found to be well organised in 
the physiological orientation, parallel to the collagen fibres. 
In the deep zone, no detectable elastin fibres were observed. 
In the elastin‑containing superficial cartilage, inflammation 
was concomitant with elastolysis, leading to the generation of 
elastin‑digested peptides (21‑23). In these cases, a direct asso‑
ciation between inflammation and elastin‑digested peptide 
levels has been previously established (21‑23). In the present 
study, immunostaining showed that MMP‑12 was expressed 
in the chondrocytes in the superficial zones where elastin 
is found physiologically. These data suggest that MMP‑12 
directly digested elastin in the superficial zone of the carti‑
lage and produced elastin‑digested peptides. Our previous 
study demonstrated that the concentration of elastin‑digested 
peptides in the synovial fluid of patients with TMJD was 
significantly correlated with IL‑6 expression, the duration 
of TMJ locking and the VAS (13). IL‑6 is generated at the 
inflammation site and plays a major role in the acute phase 
response (24). In the present study, immunostaining showed 
that IL‑6 was expressed in the chondrocytes in the superfi‑
cial zones where metalloelastase‑12 is expressed during the 
initial and early joint pathology caused by OA. These data 
suggested that elastin peptides digested by MMP‑12 induced 
IL‑6 expression in the chondrocytes in the superficial zone of 
the cartilage. However, whether the elastin‑digested peptides 
induced IL‑6 expression directly in the chondrocytes, in vitro 
or in vivo, remains unclear. In this study, it was not possible 
to detect elastin‑digested peptides in the joint fluid, as, if they 
were present, their levels were below the limits of detection. 
Further research using joint tissue‑specific elastin–overex‑
pressing mice or joint tissue‑specific elastin knockout mice 
is warranted. In contrast, in the subchondral bone, MMP‑12 
expression was observed in osteoblast‑ and osteoclast‑like 
cells in the 20‑week‑old STR/Ort mice and the frequency of 
occurrence increased with disease severity until the mice were 
40 weeks old. In a previous study, it was shown that MMP‑12 
was present in the matrix adjacent to the osteoblast‑like cells, 
bone lining cells and osteoclasts in moderate and severe stages 
of OA (25). In vitro and in vivo animal studies revealed that 
MMP‑12 cleaved bone matrix proteins critical for osteoclast 
matrix interactions, and this was induced only in response 
to critical situations (26). However, elastin fibres have not 
been detected in the subchondral bone. A total of 90% of the 
organic matrix of bone is made of type I collagen, which is 
not degradable by MMP‑12 (27). From a quantitative point 
of view, non‑collagenous bone proteins, such as vitronectin, 
osteonectin, osteopontin and bone sialoprotein, are minimally 
present in the bone (26). It is thus interesting that vitronectin 
and osteonectin are completely degraded by MMP‑12, but that 
osteopontin and bone sialoprotein are cleaved in a very selec‑
tive way (28). Therefore, the degradation fragments of these 
minor bone proteins may potentially induce IL‑6 expression 
in osteoblasts and osteoclasts. Further research is necessary to 
address this issue.
Following the onset of the inflammatory response, IL‑6 
secreted in the TMJ may function as a chemoattractant to 
recruit cell types that are crucial in tissue degradation (13). 
The stimulation of cartilage explants with IL‑6 potentiated 
proteoglycan (aggrecan) catabolism in the articular cartilage 
has been previously reported (29). This catabolism was found 
to be associated with aggrecanase activity. The aggreca‑
nases are members of the ADAMTS family of extracellular 
metzincin proteinases. Amongst the various members of this 
family of proteins, ADAMTS‑4 and ADAMTS‑5 show the 
highest levels of aggrecanase activity (30). Mice deficient in 
ADAMTS‑5 were protected against aggrecan loss and carti‑
lage degradation in models of inflammatory arthritis (31) and 
OA (32). In this regard, IL‑6 upregulation is critical for the 
progression of arthritic diseases. IL‑6 contributes to cartilage 
destruction in mouse models of inflammatory arthritis (33,34); 
as per one report, aggrecan loss is prevented in IL‑6‑deficient 
mice (34). IL‑6 increases the mRNA expression levels of 
ADAMTS‑4 and ADAMTS‑5 in bovine chondrocytes (35). 
Moreover, IL‑6–null mice are protected against cartilage 
damage both in the CIA model (36) and the antigen‑induced 
arthritis model (33). In the present study, immunostaining 
revealed that ADAMTS‑4 and ADAMTS‑5 were expressed 
in chondrocytes in the superficial zones where IL‑6 was 
expressed during the initial and early joint pathology caused 
by OA. These data suggested that IL‑6 induced ADAMTS‑4 
and ADAMTS‑5 expression in the chondrocytes, following 
cartilage degradation in the superficial zone in vivo.
In conclusion, a model for the initiation of the inflamma‑
tory and degradative process in the TMJ is proposed. Harmful 
mechanical stimuli, particularly increased pressure, may cause 
damage to the elastin fibres in the most elastin‑rich superfi‑
cial layer of the articular cartilage. Elastin‑digested peptides 
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are then generated as endogenous danger signals and induce 
a pro‑inflammatory cascade. This leads to upregulation of 
pro‑inflammatory mediators, such as IL‑6 and MMP‑12, trig‑
gering further tissue damage that results in increased levels 
of elastin‑digested peptides. IL‑6 induced ADAMTS‑4 and 
ADAMTS‑5 expression in the chondrocytes, following carti‑
lage degradation. Thus, a positive feedback loop is established 
and may result in chronic inflammation and cartilage degrada‑
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